GHRH-analogue research peptide · without DAC
3mL vial
CJC-1295 without DAC, commonly referred to as modified GRF (1–29), is a synthetic analogue of growth hormone–releasing hormone (GHRH). It is investigated for GHRH receptor activity and growth hormone / IGF-1 signalling. It does not contain the drug affinity complex (DAC) and is distinct from the longer-acting CJC-1295 with DAC.
Claims about muscle growth, fat loss, recovery or anti-ageing are not established benefits of this research product. It is not TGA approved for human use. Human use can carry risks, including effects on blood glucose, fluid retention and injection-related complications.
Supplied for in-vitro laboratory research only. Not for human consumption — no health or therapeutic effect is claimed or implied.
- GHRH receptor binding assays
- Growth hormone / IGF-1 signalling studies
- Comparative GHRH-analogue research